
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is a well-established and well-diversified company in the medical technology industry. With a strong product portfolio and a global presence, Medtronic is positioned for continued growth and success. Their recent divestment of the diabetes business may lead to short-term challenges, but their focus on new product launches and efficiency improvements should drive long-term growth. With potential upside drivers such as the acquisition of Scientia Vascular and better than expected sales and margins, Medtronic has the potential to outperform expectations and deliver strong returns for investors.
Bears say
Medtronic is expected to experience minimal dilution to its adjusted EPS in FY27 from the acquisition of Scientia Vascular and plans to continue pursuing tuck-in acquisitions to drive future organic growth, despite recent weakness in certain product categories leading to a lower 6.0% Y/Y organic growth in F3Q26, lower than our base case assumption.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares